TransMedics initiated with an Equal Weight at Morgan Stanley. Morgan Stanley analyst David Lewis started TransMedics with an Equal Weight rating and $32 price target, stating that while the company’s Organ Care System is a “paradigm shifting technology” poised to disrupt organ transplantation, he thinks the stock’s valuation represents a balanced risk/reward in the near-term.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.